Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have successfully completed the ALZA screening protocol C-98-011 within the past six months~* taking or have taken in the past 5 - 20 mg of immediate-release methylphenidate (Ritalin®) at least twice a day, 20 - 60 mg of sustained-release methylphenidate (Ritalin-SR®) per day, or a combination of immediate-release and sustained-release methylphenidate up to a daily dose not exceeding 60 mg, or have successfully completed ALZA Protocol C-98-007~* agreeing to take only the supplied study drug as treatment for ADHD during the four-week treatment phase of the study~* who are able to comply with the study visit schedule and whose parent(s) and teacher are willing and able to complete the protocol-specified assessments~* having normal urinalysis, hematological and blood chemistry values or, if values are outside the normal range, they are determined to be not clinically significant by the investigator~Exclusion Criteria:~* Patients who have clinically significant gastrointestinal problems, including narrowing of the gastrointestinal tract~* having glaucoma, an ongoing seizure disorder, a psychotic disorder, clinical depression (and are suicidal or require immediate treatment for depression), or a diagnosis of Tourette's syndrome~* having a known allergy to methylphenidate or currently having significant adverse experiences from methylphenidate~* having a mean of two blood pressure measurements (systolic or diastolic) equal to or greater than the 95th percentile for age, sex, and height at screening~* if female, have begun menstruation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): OROS methylphenidate HCl
- 002 (Type: ACTIVE_COMPARATOR): Ritalin
- 003 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).